Results 41 to 50 of about 184,499 (325)

Src Inhibition Can Synergize with Gemcitabine and Reverse Resistance in Triple Negative Breast Cancer Cells via the AKT/c-Jun Pathway. [PDF]

PLoS ONE, 2016
Gemcitabine-based chemotherapy remains one of the standards in management of metastatic breast cancer. However, intrinsic and acquired resistance to gemcitabine inevitably occurs.
Zhen-Hua Wu, Chen Lin, Ming-Ming Liu, Jian Zhang, Zhong-Hua Tao, Xi-Chun Hu   +5 more
doaj   +1 more source

Recent Development of Prodrugs of Gemcitabine

Genes, 2022
Gemcitabine is a nucleoside analog that has been used widely as an anticancer drug for the treatment of a variety of conditions, including ovarian, bladder, non-small-cell lung, pancreatic, and breast cancer. However, enzymatic deamination, fast systemic
Bhoomika Pandit, M. Royzen
semanticscholar   +1 more source

Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline BRCA/PALB2 Mutation.

Journal of Clinical Oncology, 2020
PURPOSE Five percent to 9% of pancreatic ductal adenocarcinomas (PDACs) develop in patients with a germline BRCA1/2 or PALB2 (gBRCA/PALB2+) mutation. Phase IB data from a trial that used cisplatin, gemcitabine, and veliparib treatment demonstrated a high
E. O’Reilly, Jonathan W. Lee, M. Zalupski, M. Capanu, Jennifer Park, T. Golan, E. Tahover, M. Lowery, J. Chou, V. Sahai, R. Brenner, H. Kindler, Kenneth H. Yu, A. Zervoudakis, S. Vemuri, Z. Stadler, R. Do, N. Dhani, A. Chen, D. Kelsen   +19 more
semanticscholar   +1 more source

Prognostic and therapeutic significance of carbohydrate antigen 19-9 as tumor marker in patients with pancreatic cancer [PDF]

, 2006
In pancreatic cancer ( PC) accurate determination of treatment response by imaging often remains difficult. Various efforts have been undertaken to investigate new factors which may serve as more appropriate surrogate parameters of treatment efficacy ...
Anderson JS, Bekaii-Saab TS, Brambs HJ, Burris HA, Ebrahimi B, Glenn J, Gogas H, Goggins M, Heinemann V, Heinemann V, Heinemann V, Ishii H, Jamieson NB, Jiang XT, Katz A, Ko AH, Koprowski H, Louvet C, Lundin J, Maisey NR, Montgomery RC, Moore MJ, Ni XG, Okusaka T, Petra Stieber, Philip PA, Ralf Wilkowski, Saad ED, Safi F, Safi F, Sakar B, Sawaki A, Sperti C, Stathopoulos GP, Stefan Boeck, Stefan Holdenrieder, Steinberg W, Tanaka N, Tempero MA, Tian F, van Custem E, Vimalachandran D, Volker Heinemann, Wilkowski R, Wilkowski R, Wilkowski R, Willet CG, Wolff RA, Ziske C   +48 more
core   +1 more source

Knockdown of clusterin sensitizes pancreatic cancer cells to gemcitabine chemotherapy by ERK1/2 inactivation

Journal of Experimental & Clinical Cancer Research, 2012
Objectives To study the hypothesis that gemcitabine treatment augments the chemoresistance to gemcitabine by clusterin (sCLU) upregulation. Clusterin inhibition could augment the chemosensitivity of human pancreatic cancer cells by inhibition of ...
Tang Yong, Liu Fenghua, Zheng Chunning, Sun Shaochuan, Jiang Yingsheng   +4 more
doaj   +1 more source

Chloroquine plays a cell-dependent role in the response to treatment of pancreatic adenocarcinoma [PDF]

, 2018
In this study, our aim is to assess the role played by autophagy and its inhibition in the different PDAC cellular compartments, and its involvement in chemo-resistance using primary human pancreatic cancer-derived cells (PCC) and Cancer Associated ...
Bintz, Jennifer, Fanale, Daniele, Gayet, Odile, Iovanna, Juan Lucio, Molejon, Maria Ines, Soubeyran, Philippe, Swayden, Mirna   +6 more
core   +1 more source

Clinical outcomes of chemotherapy in patients with undifferentiated carcinoma of the pancreas: a retrospective multicenter cohort study

BMC Cancer, 2020
Background Undifferentiated carcinoma (UC) of the pancreas is a rare subtype of pancreatic cancer. Although UC has been considered a highly aggressive malignancy, no clinical studies have addressed the efficacy of chemotherapy for unresectable UC ...
Hiroshi Imaoka, Masafumi Ikeda, Kosuke Maehara, Kumiko Umemoto, Masato Ozaka, Satoshi Kobayashi, Takeshi Terashima, Hiroto Inoue, Chihiro Sakaguchi, Kunihiro Tsuji, Kazuhiko Shioji, Keiya Okamura, Yasuyuki Kawamoto, Rei Suzuki, Hirofumi Shirakawa, Hiroaki Nagano, Makoto Ueno, Chigusa Morizane, Junji Furuse   +18 more
doaj   +1 more source

Alternative polyadenylation of ZEB1 promotes its translation during genotoxic stress in pancreatic cancer cells [PDF]

, 2017
Pancreatic ductal adenocarcinoma (PDAC) is characterized by extremely poor prognosis. The standard chemotherapeutic drug, gemcitabine, does not offer significant improvements for PDAC management due to the rapid acquisition of drug resistance by patients.
Bielli, Pamela, Capurso, Gabriele, Delle Fave, Gianfranco, Farini, Donatella, Panzeri, Valentina, Passacantilli, Ilaria, Pilozzi, Emanuela, Sette, Claudio   +7 more
core   +2 more sources

SLC39A1 contributes to gemcitabine resistance of pancreatic ductal adenocarcinoma by activating AMPK signaling

Bangladesh Journal of Pharmacology
Gemcitabine is a common first-line chemotherapy agent, but gemcitabine resistance is a clinical challenge for pancreatic ductal adenocarcinoma patients.
Hao Yu, Xiaoping Mei, Xueming Zhang, Neng Qian, Qingjiang Yu, Hongkun Zhou   +5 more
doaj   +1 more source

Gemcitabine based combination chemotherapy in advanced pancreatic cancer-indirect comparison

BMC Cancer, 2008
Background Recent meta-analyses have found a survival advantage with gemcitabine based combinations over single agent gemcitabine in patients with advanced pancreatic cancer.
Neoptolemos John P, Starling Naureen, Cunningham David, Ghaneh Paula, Sultana Asma, Smith Catrin   +5 more
doaj   +1 more source